Sublingual buprenorphine for treatment of neonatal abstinence syndrome: A randomized trial

Pediatrics

Volumn 122, Issue 3, 2008, Pages

  Kraft, Walter K ^a   Gibson, Eric ^a,b   Dysart, Kevin ^a,b   Damle, Vidula S ^a,b   Larusso, Jennifer L ^a   Greenspan, Jay S ^a,b   Moody, David E ^c   Kaltenbach, Karol ^a   Ehrlich, Michelle E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Morphine; Neonatal abstinence syndrome; Sublingual drug administration

Indexed keywords

BUPRENORPHINE; MORPHINE; PHENOBARBITAL; NARCOTIC ANTAGONIST;

ABSTINENCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NEWBORN; OPEN STUDY; OPIATE ADDICTION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEIZURE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DETOXIFICATION; FOLLOW UP; GESTATIONAL AGE; RETROSPECTIVE STUDY; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; METABOLIC DETOXICATION, DRUG; NARCOTIC ANTAGONISTS; NEONATAL ABSTINENCE SYNDROME; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 51649115603     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0571     Document Type: Article

References (37)

1. Vega WA, Kolody B, Hwang J, Noble A. Prevalence and magnitude of perinatal substance exposures in California. N Engl J Med. 1993;16:329(12):850-854
2. American Academy of Pediatrics, Committee on Drugs. Neonatal drug withdrawal [published correction appears in Pediatrics. 1998;102(3pt 1):660]. Pediatrics. 1998;101(6):1079-1088
3. Nandakumar N, Sankar VS. What is the best evidence based management of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2006;91(6):F463
4. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006;1:26(1):15-17
5. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005;(3):CD002059
6. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2005; (3):CD002053
7. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2003; 88(1):F2-F5
8. Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Haga- dorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with metha- done versus oral morphine preparations. Adv Neonatal Care. 2005;5(5):265-272
9. Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. DrugAlcohol Depend. 2005;77(1):31-36
10. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002; 140(5):561-564
11. Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2004; 89(4):F300-F304
12. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3): 277-288
13. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569-580
14. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high- dose methadone. Ann Intern Med. 2002;137(6):501-504
15. Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and phar- macokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101-110
16. Michel E, Zernikow B. Buprenorphine in children: a clinical and pharmacological review [in German]. Schmerz. 2006;20(1):40-50
17. Barrett DA, Simpson J, Rutter N, Kurihara-Bergstrom T, Shaw PN, Davis SS. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol. 1993;36(3):215-219
18. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther. 1997;62(5):569-571
19. Maunuksela EL, Korpela R, Olkkola KT. Comparison of bu- prenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg. 1988;67(3):233-239
20. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson N, Seidel HM, eds. Primary Pediatric Care. 2nd ed. St Louis, MO: Mosby; 1992: 1367-1378
21. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid- dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1-10
22. Mamelle N, Cochet V, Claris O. Definition of fetal growth restriction according to constitutional growth potential. Biol Neonate. 2001;80(4):277-285
23. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ioniza- tion-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a cofor- mulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31-39
24. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006;34(3):440-448
25. Mizrahi EM, Kellaway P. Diagnosis and Management of Neonatal Seizures. Philadelphia, PA: Lippincott-Raven; 1998
26. Jansson LM, Dipietro JA, Elko A, Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med. 2007;20(9):677-685
27. Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998;93(4):549-559
28. Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review: part 1-pharmacokinetics. Paediatr Anaesth. 1997; 7(1):5-11
29. Huang W, Moody DE, McCance-Katz EF. The in vivo glucu- ronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization- tandem mass spectrometry. Ther Drug Monit. 2006;28(2): 245-251
30. McGrath C, Buist A, Norman TR. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. Drug Saf. 1999;20(2):171-186
31. Myllynen P, Vahakangas K. An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods. 2002;48(3):131-138
32. Wikner BN, Stiller CO, Kallen B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf. 2007;16(9):988-994
33. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6). Available at: www.pediatrics.org/ cgi/content/full/117/6/e1163
34. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther. 2008;83(1):181-183
35. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double- dummy comparison study. Addiction. 2006;101(2):275-281
36. Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmes- maki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand. 2007;86(2):185-190
37. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;21:70(2 suppl):S87-S101